Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;12(6):651-660.
doi: 10.1007/s40271-019-00394-7.

Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials

Eric S Surrey  1 , Ahmed M Soliman  2 , Hannah L Palac  2 , Sanjay K Agarwal  3
Affiliations

Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials

Eric S Surrey et al. Patient. 2019 Dec.

Abstract

Background: Endometriosis profoundly impairs women's workplace and household productivity.

Objective: The aim of this study was to evaluate the impact of elagolix on endometriosis-related workplace and household productivity losses.

Methods: Data were pooled from two phase III trials of women aged 18-49 years with moderate to severe endometriosis-associated pain treated for 6 months with elagolix 150 mg daily (QD), 200 mg twice daily (BID), or placebo. The Health-Related Productivity Questionnaire was administered at baseline, Month 3, and Month 6 to determine workplace and household absenteeism and presenteeism. Productivity changes from baseline were compared between placebo and elagolix doses via analysis of covariance.

Results: Workplace analyses included 1270 employed women and household analyses included 1565 women. At baseline, women reported average weekly losses of 16 workplace hours, 8.3 household work hours, 45% of scheduled work, and 64% of planned household chores. At Month 6, treatment with elagolix 150 mg QD or 200 mg BID increased productive workplace hours by 1.7 (95% CI 0.1-3.4; p = 0.041) and 5.4 h (95% CI 3.7-7.1; p < 0.001) relative to placebo, corresponding to gains of 5.2% (95% CI 0.7-9.7; p = 0.022) and 14.6% (95% CI 10.0-19.1; p < 0.001) of scheduled work, respectively. Both elagolix doses improved household productivity at Month 6 by 1.7 (95% CI 0.7-2.7) and 3.1 (95% CI 2.1-4.0) hours relative to placebo (both p < 0.001), with increases of 8.8% (95% CI 3.5-14.1; p = 0.001) and 20.4% (95% CI 15.1-25.6; p < 0.001) of planned household work.

Conclusions: Treatment with elagolix improved endometriosis-related workplace and household productivity impairments.

Trial registration: ELARIS EM-I (NCT01620528) and ELARIS EM-II (NCT01931670).

PubMed Disclaimer

Conflict of interest statement

Eric S. Surrey is Medical Director at Colorado Center for Reproductive Medicine, has served in a consulting role for AbbVie and DOT Laboratories, received research grants from AbbVie, and served on the speaker bureau for AbbVie and Ferring Laboratories. Ahmed M. Soliman is an employee of, owns stock/stock options, and holds patents for AbbVie. Hannah L. Palac was an employee of AbbVie Inc. at the time the research was conducted. Sanjay K. Agarwal is Director of Fertility Services in the UC San Diego Department of Reproductive Medicine, Director of the UC San Diego Center for Endometriosis Research and Treatment, and has served in a consulting role on research for AbbVie Inc. and has received research support from AbbVie Inc.

Figures

Fig. 1
Fig. 1
Gains in productive workplace hours per week at Months 3 and 6 of treatment. Mean hours gained in workplace productivity from baseline, defined as − 1 × LS mean change from baseline in hours of workplace productivity lost due to absenteeism, presenteeism, and total hours lost (absenteeism + presenteeism). ***p < 0.001; **p < 0.01; *p < 0.05. BID twice daily, CI confidence interval, LS least squares, PBO placebo, QD once daily
Fig. 2
Fig. 2
Gains in percentage of scheduled workplace productivity per week at Months 3 and 6 of treatment. Mean gains in the percentage of scheduled workplace hours worked, defined as − 1 × LS mean change from baseline in percentage of scheduled workplace hours lost due to absenteeism, presenteeism, and total (absenteeism + presenteeism). ***p < 0.001; **p < 0.01; *p < 0.05. BID twice daily, CI confidence interval, LS least squares, PBO placebo, QD once daily
Fig. 3
Fig. 3
Gains in hours of household productivity per week at Months 3 and 6 of treatment. Mean hours gained in household productivity, defined as − 1 × LS mean change from baseline in hours of household productivity lost due to absenteeism, presenteeism, and total (absenteeism + presenteeism). ***p < 0.001; **p < 0.01; *p < 0.05. BID twice daily, CI confidence interval, LS least squares, PBO placebo, QD once daily
Fig. 4
Fig. 4
Gains in percentage of planned household productivity per week at Months 3 and 6 of treatment. Mean gains in the percentage of planned household work hours worked, defined as − 1 × LS mean change from baseline in percentage of planned household work hours lost due to absenteeism, presenteeism, and total (absenteeism + presenteeism). ***p < 0.001; **p < 0.01; *p < 0.05. BID twice daily, CI confidence interval, LS least squares, PBO placebo, QD once daily
See this image and copyright information in PMC

References

    1. Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013;19(4):406–418. doi: 10.1093/humupd/dmt010. - DOI - PMC - PubMed
    1. Fuldeore MJ, Soliman AM. Prevalence and symptomatic burden of diagnosed endometriosis in the United States: national estimates from a cross-sectional survey of 59,411 women. Gynecol Obstet Invest. 2017;82(5):453–461. doi: 10.1159/000452660. - DOI - PubMed
    1. Abbas S, Ihle P, Koster I, Schubert I. Prevalence and incidence of diagnosed endometriosis and risk of endometriosis in patients with endometriosis-related symptoms: findings from a statutory health insurance-based cohort in Germany. Eur J Obstet Gynecol Reprod Biol. 2012;160(1):79–83. doi: 10.1016/j.ejogrb.2011.09.041. - DOI - PubMed
    1. Wheeler JM. Epidemiology of endometriosis-associated infertility. J Reprod Med. 1989;34(1):41–46. - PubMed
    1. Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20(10):2698–2704. doi: 10.1093/humrep/dei135. - DOI - PubMed

Publication types

Associated data